Guillain Barre syndrome (GBS): pathogenesis

Evidence-based neurology checklist on guillain barre syndrome (gbs): pathogenesis: Antiganglioside antibodies Anti GM1: these are present in up to 50% of cases Anti GQ1b: this is seen in 9% of cases of Miller Fisher syndrome (MFS) Anti GT1a: this is seen in 10% of cases especially with cranial…

Antiganglioside antibodies

  • Anti GM1: these are present in up to 50% of cases
  • Anti GQ1b: this is seen in 9% of cases of Miller Fisher syndrome (MFS)
  • Anti GT1a: this is seen in 10% of cases especially with cranial nerve involvement
  • AntiGD1: this is seen in 8% of cases: especially in severe motor axonal GBS
  • AntiPMP22: this is seen in >50% of cases

Paranodal antibodies

Other antibodies

References

  1. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999; 100:74-97.
  2. Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain-Barre syndrome. JNNP 2002; 72:767-771.
  3. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 2004; 56:567-571.
  4. Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000; 104:139-146.
  5. Querol L, Illa I. Paranodal and other autoantibodies in chronic inflammatory neuropathies. Curr Opin Neurol 2015; 28:474-479.
  6. And 7 more. Subscribe to see the full list

Related checklists

Loading...